Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis.

9 , 54 Another small study found no significant difference in terms of overall survival between solid-tumor and hematologic patients, although patients with a hematologic malignancy showed a nonsignificant trend for earlier occurrence of severe events compared with solid-tumor patients. 61 Among cancer patients with COVID-19, cancer type 6 and active treatment with chemotherapy, immunotherapy, targeted therapies, hormonal therapy, surgery, or radiotherapy within four weeks of diagnosis were not associated with increased adverse outcomes. 46 Unlike these studies that looked at all patients with cancer and COVID-19, our study was focused on cancer patients with COVID-19 admitted to the ICU or those with severe disease.

also in 5,406 other papers